 Tamoxifen
"Tamoxifen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.
| Descriptor ID |
D013629
|
| MeSH Number(s) |
D02.455.426.559.389.150.700.900
|
| Concept/Terms |
ICI-46474- ICI-46474
- ICI 46474
- ICI46474
- ICI-46,474
- ICI 46,474
- ICI46,474
|
Below are MeSH descriptors whose meaning is more general than "Tamoxifen".
Below are MeSH descriptors whose meaning is more specific than "Tamoxifen".
This graph shows the total number of publications written about "Tamoxifen" by people in this website by year, and whether "Tamoxifen" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1992 | 1 | 1 | 2 | | 1993 | 2 | 0 | 2 | | 1994 | 3 | 1 | 4 | | 1995 | 1 | 0 | 1 | | 1997 | 1 | 0 | 1 | | 1998 | 1 | 1 | 2 | | 1999 | 2 | 2 | 4 | | 2000 | 3 | 2 | 5 | | 2001 | 0 | 1 | 1 | | 2002 | 1 | 0 | 1 | | 2003 | 2 | 1 | 3 | | 2004 | 2 | 2 | 4 | | 2005 | 0 | 1 | 1 | | 2006 | 2 | 1 | 3 | | 2007 | 3 | 3 | 6 | | 2008 | 5 | 1 | 6 | | 2009 | 3 | 3 | 6 | | 2010 | 3 | 4 | 7 | | 2011 | 0 | 1 | 1 | | 2012 | 1 | 3 | 4 | | 2013 | 1 | 1 | 2 | | 2014 | 3 | 6 | 9 | | 2015 | 0 | 1 | 1 | | 2016 | 3 | 4 | 7 | | 2017 | 1 | 2 | 3 | | 2018 | 0 | 4 | 4 | | 2019 | 1 | 5 | 6 | | 2020 | 3 | 1 | 4 | | 2021 | 1 | 5 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Tamoxifen" by people in Profiles.
-
Friedman JC, Buyers E, Laurin J, Hampanda K, Alaniz VI. Tamoxifen for the Treatment of Etonogestrel Implant-Associated Bleeding in an Adolescent Gynecology Practice. J Pediatr Adolesc Gynecol. 2022 Jun; 35(3):341-345.
-
Scalzo RL, Foright RM, Hull SE, Knaub LA, Johnson-Murguia S, Kinanee F, Kaplan J, Houck JA, Johnson G, Sharp RR, Gillen AE, Jones KL, Zhang AMY, Johnson JD, MacLean PS, Reusch JEB, Wright-Hobart S, Wellberg EA. Breast Cancer Endocrine Therapy Promotes Weight Gain With Distinct Adipose Tissue Effects in Lean and Obese Female Mice. Endocrinology. 2021 11 01; 162(11).
-
Sukumar JS, Quiroga D, Kassem M, Grimm M, Shinde NV, Appiah L, Palettas M, Stephens J, Gatti-Mays ME, Pariser A, Cherian M, Stover DG, Williams N, Van Deusen J, Wesolowski R, Lustberg M, Ramaswamy B, Sardesai S. Patient preferences and adherence to adjuvant GnRH analogs among premenopausal women with hormone receptor positive breast cancer. Breast Cancer Res Treat. 2021 Nov; 190(2):183-188.
-
Stout MB, Scalzo RL, Wellberg EA. Persistent Metabolic Effects of Tamoxifen: Considerations for an Experimental Tool and Clinical Breast Cancer Treatment. Endocrinology. 2021 09 01; 162(9).
-
Partridge AH, Niman SM, Ruggeri M, Peccatori FA, Azim HA, Colleoni M, Saura C, Shimizu C, Sætersdal AB, Kroep JR, Mailliez A, Warner E, Borges VF, Amant F, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Walshe JM, Borrego MR, Moore HC, Saunders C, Cardoso F, Susnjar S, Bjelic-Radisic V, Smith KL, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagani O. Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy. Breast. 2021 Oct; 59:327-338.
-
Sottnik JL, Bordeaux EK, Mehrotra S, Ferrara SE, Goodspeed AE, Costello JC, Sikora MJ. Mediator of DNA Damage Checkpoint 1 (MDC1) Is a Novel Estrogen Receptor Coregulator in Invasive Lobular Carcinoma of the Breast. Mol Cancer Res. 2021 08; 19(8):1270-1282.
-
Bhatia S, Palomares MR, Hageman L, Chen Y, Landier W, Smith K, Umphrey H, Reich CA, Zamora KW, Armenian SH, Bevers TB, Blaes A, Henderson T, Hodgson D, Hudson MM, Korde LA, Melin SA, Merajver SD, Overholser L, Pruthi S, Wong FL, Garber JE. A Randomized Phase IIb Study of Low-dose Tamoxifen in Chest-irradiated Cancer Survivors at Risk for Breast Cancer. Clin Cancer Res. 2021 02 15; 27(4):967-974.
-
Wahdan-Alaswad RS, Edgerton SM, Salem H, Kim HM, Tan AC, Finlay-Schultz J, Wellberg EA, Sartorius CA, Jacobsen BM, Haugen BR, Liu B, Thor AD. Exogenous Thyroid Hormone Is Associated with Shortened Survival and Upregulation of High-Risk Gene Expression Profiles in Steroid Receptor-Positive Breast Cancers. Clin Cancer Res. 2021 01 15; 27(2):585-597.
-
Golla JP, Kandyliari A, Tan WY, Chen Y, Orlicky DJ, Thompson DC, Shah YM, Vasiliou V. Interplay between APC and ALDH1B1 in a newly developed mouse model of colorectal cancer. Chem Biol Interact. 2020 Nov 01; 331:109274.
-
Novick AM, Scott AT, Neill Epperson C, Schneck CD. Neuropsychiatric effects of tamoxifen: Challenges and opportunities. Front Neuroendocrinol. 2020 10; 59:100869.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|